Nothing Special   »   [go: up one dir, main page]

GB201908511D0 - Hydroxamate compounds - Google Patents

Hydroxamate compounds

Info

Publication number
GB201908511D0
GB201908511D0 GBGB1908511.7A GB201908511A GB201908511D0 GB 201908511 D0 GB201908511 D0 GB 201908511D0 GB 201908511 A GB201908511 A GB 201908511A GB 201908511 D0 GB201908511 D0 GB 201908511D0
Authority
GB
United Kingdom
Prior art keywords
hydroxamate compounds
hydroxamate
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1908511.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adorx Therapeutics Ltd
Original Assignee
Adorx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adorx Therapeutics Ltd filed Critical Adorx Therapeutics Ltd
Priority to GBGB1908511.7A priority Critical patent/GB201908511D0/en
Publication of GB201908511D0 publication Critical patent/GB201908511D0/en
Priority to PCT/GB2020/051432 priority patent/WO2020260857A1/en
Ceased legal-status Critical Current

Links

GBGB1908511.7A 2019-06-13 2019-06-13 Hydroxamate compounds Ceased GB201908511D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1908511.7A GB201908511D0 (en) 2019-06-13 2019-06-13 Hydroxamate compounds
PCT/GB2020/051432 WO2020260857A1 (en) 2019-06-13 2020-06-12 Hydroxamate compounds as antagonists of the adenosine a2a receptor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1908511.7A GB201908511D0 (en) 2019-06-13 2019-06-13 Hydroxamate compounds

Publications (1)

Publication Number Publication Date
GB201908511D0 true GB201908511D0 (en) 2019-07-31

Family

ID=67432163

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1908511.7A Ceased GB201908511D0 (en) 2019-06-13 2019-06-13 Hydroxamate compounds

Country Status (2)

Country Link
GB (1) GB201908511D0 (en)
WO (1) WO2020260857A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427993B (en) 1993-09-09 2001-04-01 Fujisawa Pharmaceutical Co New cephem compounds
BRPI0409366A (en) 2003-04-10 2006-04-25 Hoffmann La Roche pyrimidine compounds
WO2007034277A1 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists
BRPI0720522A2 (en) 2006-12-22 2014-01-07 Actelion Pharmaceuticals Ltd 5,6,7,8-TETRAHYDROIMIDAZO [1,5-A] PIRAZINE DERIVATIVE COMPOUND AND USE OF THIS OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
AU2009225869B2 (en) * 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
TW201102390A (en) 2009-03-31 2011-01-16 Arqule Inc Substituted pyrazolo-pyrimidine compounds
KR20120089463A (en) 2009-08-20 2012-08-10 노파르티스 아게 Heterocyclic oxime compounds
GB201001070D0 (en) 2010-01-22 2010-03-10 St George's Hospital Medical School Theraputic compounds and their use
RS61242B1 (en) 2012-09-04 2021-01-29 Shanghai hengrui pharmaceutical co ltd Imidazoline derivatives, preparation methods thereof, and their applications in medicine
CN103664908A (en) * 2013-12-10 2014-03-26 苏州大学 Aminopyrimidine heterocyclic compound having adenosine receptor antagonizing activity
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
GB201721751D0 (en) * 2017-12-22 2018-02-07 Adorx Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
WO2020260857A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
IL292753A (en) Compounds
IL289463A (en) Gipr-agonist compounds
GB201905721D0 (en) Compounds
GB201916915D0 (en) Compounds
GB201910305D0 (en) Compounds
GB201908536D0 (en) Compounds
GB201908171D0 (en) Compounds
GB201908511D0 (en) Hydroxamate compounds
IL291322A (en) Acrylamide compounds
GB201910304D0 (en) Compounds
GB201908095D0 (en) Carboxy-MIDA-boronate compounds
GB201919205D0 (en) Compounds
GB201918761D0 (en) Compounds
GB201918424D0 (en) Compounds
GB201917895D0 (en) Compounds
GB201917893D0 (en) Compounds
GB201917891D0 (en) Compounds
GB201916847D0 (en) Compounds
GB201916597D0 (en) Compounds
GB201916595D0 (en) Compounds
GB201916572D0 (en) Compounds
GB201916142D0 (en) Compounds
GB201914208D0 (en) Compounds
GB201913633D0 (en) Compounds
GB201913541D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)